Detail page

Knowledge Web

Person

Alexander Robert Haug (1976-)

Arzt

Name	Alexander Robert Haug
Time	1976- (Date of birth and death)
Place	Wien (Wirkungsort) Bogen (Geburtsort) Österreich
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Arzt (characteristic profession) Nuklearmediziner Hochschullehrer
Variant	Alexander Haug (Metadaten) Alexander R. Haug A. Haug
Related	Universitätsklinik für Radiologie und Nuklearmedizin (Wien) (Privatdozent)
Further information	Promotion Ludwig-Maximilians-Universität München
Source	Homepage: https://www.dr-haug.at/ (Stand: 16.09.2021) OBV: https://permalink.obvsg.at/AC15596152 (Stand: 14.12.2020)
Record type	Person
GND-Identifier	134245733
Record ID	134245733
Involved in show all Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer—a cross-sectional study Multicenter PET image harmonization using generative adversarial networks CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges CXCR4-targeted theranostics in hematooncology: opportunities and challenges CXCR4-targeted theranostics in hematooncology: opportunities and challenges = CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer Accuracy of PET quantification in [68Ga]Ga-pentixafor PET/MR imaging of carotid plaques Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? Hybridbildgebung bei Lymphom Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks [68Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma [11C]acetate PET as a tool for diagnosis of liver steatosis Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment Current status of theranostics in prostate cancer [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system Management von Tumoren mit neuroendokriner Differenzierung Neuroendokrine Tumoren Wertigkeit der hochauflösenden craniellen Computertomographie in der Diagnose von Frakturen der Schädelbasis Wertigkeit der hochauflösenden craniellen Computertomographie in der Diagnose von Frakturen der Schädelbasis

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Alexander Robert Haug (1976-)

Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer—a cross-sectional study

Multicenter PET image harmonization using generative adversarial networks

CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges

CXCR4-targeted theranostics in hematooncology: opportunities and challenges

CXCR4-targeted theranostics in hematooncology: opportunities and challenges = CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen

Machine learning predictive performance evaluation of conventional and fuzzy radiomics in clinical cancer imaging cohorts

Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer

Added value of quantitative, multiparametric 18F-FDG PET/MRI in the locoregional staging of rectal cancer

Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer

Accuracy of PET quantification in [68Ga]Ga-pentixafor PET/MR imaging of carotid plaques

Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma

Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?

Hybridbildgebung bei Lymphom

Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

[68Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery

Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer

The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma

[11C]acetate PET as a tool for diagnosis of liver steatosis

Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment

Current status of theranostics in prostate cancer

[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques

The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy

Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system

Management von Tumoren mit neuroendokriner Differenzierung

Neuroendokrine Tumoren

Wertigkeit der hochauflösenden craniellen Computertomographie in der Diagnose von Frakturen der Schädelbasis

Wertigkeit der hochauflösenden craniellen Computertomographie in der Diagnose von Frakturen der Schädelbasis